

GraÅ¼yna WÃ³jcicka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268142/publications.pdf>

Version: 2024-02-01

31
papers

1,216
citations

430874

18
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

1827
citing authors

#	ARTICLE	IF	CITATIONS
1	Shotgun Lipidomic Analysis for Differentiation of Niche Cold Pressed Oils. <i>Molecules</i> , 2022, 27, 1848.	3.8	5
2	Paraoxonase 1 Phenotype and Protein N-Homocysteinylation in Patients with Rheumatoid Arthritis: Implications for Cardiovascular Disease. <i>Antioxidants</i> , 2020, 9, 899.	5.1	8
3	Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-7.	4.0	5
4	The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats. <i>European Journal of Pharmacology</i> , 2019, 850, 180-189.	3.5	6
5	Hydrogen sulfide in the regulation of insulin secretion and insulin sensitivity: Implications for the pathogenesis and treatment of diabetes mellitus. <i>Biochemical Pharmacology</i> , 2018, 149, 60-76.	4.4	67
6	Metabolic Effects of Metformin in the Failing Heart. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2869.	4.1	61
7	The pathophysiological basis of the protective effects of metformin in heart failure. <i>Postepy Higieny i Medycyny Doswiadczonej</i> , 2017, 71, 0-0.	0.1	7
8	The paraoxonase 1 (PON1), platelet-activating factor acetylhydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. <i>European Journal of Pharmacology</i> , 2016, 789, 187-194.	3.5	9
9	Differential effects of statins on endogenous H ₂ S formation in perivascular adipose tissue. <i>Pharmacological Research</i> , 2011, 63, 68-76.	7.1	85
10	Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. <i>Journal of Endocrinology</i> , 2010, 204, 191-198.	2.6	22
11	The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylhydrolase activity. <i>Life Sciences</i> , 2010, 87, 126-132.	4.3	18
12	Chronic hyperleptinemia induces resistance to acute natriuretic and NO-mimetic effects of leptin. <i>Peptides</i> , 2010, 31, 155-163.	2.4	19
13	Adverse Effects of Statins - Mechanisms and Consequences. <i>Current Drug Safety</i> , 2009, 4, 209-228.	0.6	179
14	Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic syndrome. <i>Life Sciences</i> , 2009, 85, 557-567.	4.3	26
15	Renal antioxidant enzymes and glutathione redox status in leptin-induced hypertension. <i>Molecular and Cellular Biochemistry</i> , 2008, 319, 163-174.	3.1	19
16	Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: Role in leptin-induced hypertension. <i>Biochemical Pharmacology</i> , 2008, 75, 1623-1638.	4.4	24
17	Role of extracellular signal-regulated kinases (ERK) in leptin-induced hypertension. <i>Life Sciences</i> , 2008, 82, 402-412.	4.3	19
18	Regulation of Renal Ouabain-Resistant Na ⁺ -ATPase by Leptin, Nitric Oxide, Reactive Oxygen Species, and Cyclic Nucleotides: Implications for Obesity-Associated Hypertension. <i>Clinical and Experimental Hypertension</i> , 2007, 29, 189-207.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic effects of leptin. <i>Regulatory Peptides</i> , 2007, 140, 168-177.	1.9	12
20	Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2007, 61, 736-59.	0.1	94
21	Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. <i>Life Sciences</i> , 2006, 79, 63-71.	4.3	28
22	H2O2 and Src-dependent transactivation of the EGF receptor mediates the stimulatory effect of leptin on renal ERK and Na ⁺ , K ⁺ -ATPase. <i>Peptides</i> , 2006, 27, 3234-3244.	2.4	26
23	Antioxidant treatment normalizes nitric oxide production, renal sodium handling and blood pressure in experimental hyperleptinemia. <i>Life Sciences</i> , 2005, 77, 1855-1868.	4.3	19
24	Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. <i>Pharmacological Research</i> , 2005, 51, 523-532.	7.1	37
25	Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 121-127.	1.9	31
26	Influence of intravenously administered leptin on nitric oxide production, renal hemodynamics and renal function in the rat. <i>Regulatory Peptides</i> , 2004, 120, 59-67.	1.9	30
27	Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. <i>Life Sciences</i> , 2004, 74, 2987-3000.	4.3	94
28	Bidirectional regulation of renal cortical Na ⁺ ,K ⁺ -ATPase by protein kinase C.. <i>Acta Biochimica Polonica</i> , 2004, 51, 757-772.	0.5	19
29	Stimulatory Effect of Leptin on Nitric Oxide Production Is Impaired in Dietary-Induced Obesity. <i>Obesity</i> , 2003, 11, 1571-1580.	4.0	16
30	Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. <i>Atherosclerosis</i> , 2003, 170, 21-29.	0.8	147
31	Human Leptin Stimulates Systemic Nitric Oxide Production in the Rat. <i>Obesity</i> , 2002, 10, 939-946.	4.0	53